Randomized clinical trials (RCTs) remain a central pillar of clinical development, and the adoption of AI-driven approaches can complement and enhance these traditional methods. As gen AI continues to break milestones, patients eagerly await faster access to better treatments enabled by AI-driven drug discovery.